Nomic Bio

Newomics Inc.BiotechnologyUnited States

68% matchPrivate

Newomics Inc. is a privately-held biotechnology company headquartered in California that develops and commercializes advanced mass spectrometry solutions. The company provides innovative front-end systems and analytical tools for life sciences and research markets.

Novilytic, LLCBiotechnologyUnited States

67% matchPrivate

Novilytic develops bioanalytical products and kits, notably the Proteometer platform, which streamlines protein-quality analysis for pharmaceutical laboratories. The company's technology enables rapid assessment of titer, aggregates, and charge variants for monoclonal antibodies, multispecifics, and fusion proteins while eliminating traditional sample preparation and purification steps.

Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.

Olink ProteomicsBiotechnologySweden

64% match

Olink Proteomics provides high-throughput protein biomarker analysis products, instruments, software, and analysis services for life science research and drug development. Utilizing its proprietary Proximity Extension Assay (PEA) technology and next-generation sequencing, the company serves researchers and pharmaceutical organizations focused on biomarker discovery and precision medicine.

CDI Laboratories, Inc.BiotechnologyUnited States

62% matchPrivate

CDI Laboratories, Inc. is a biotechnology company that operates Puerto Rico's first research facility dedicated to the development and commercialization of proteomic technologies.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.